Background: Glioblastoma multiforme (GBM) is the most common malignant primary brain
tumor, with an incidence of 3.19 cases per 100,000 person years and remarkably poor …

Glioblastoma is the most common primary malignant brain tumour. Survival is poor and
improved treatment options are urgently needed. Although immunotherapies have emerged …

Glioblastoma (GBM) is the most popular primary central nervous system cancer and has an
extremely expansive course. Aggressive tumor growth correlates with short median overall …

Glioblastoma (GBM) is the most devastating brain tumor, with associated poor prognosis.
Despite advances in surgery and chemoradiation, the survival of afflicted patients has not …

Glioma represents a fast proliferating and highly invasive brain tumor which is resistant to
current therapies and invariably recurs. Despite some advancements in anti-glioma …

Glioblastoma multiforme (GBM) is a malignant tumor within the brain. Generally classified as
primary and secondary with several different subtypes, ample molecular biomarkers have …

The blood–brain barrier (BBB) remains one of the most significant limitations to treatments of
central nervous system (CNS) disorders including brain tumors, neurodegenerative …

Neutrophils are the most abundant white blood cells and are the first recruited to
inflammatory sites. Neutrophils are an important component of the tumor stroma and can …

Background Glioblastoma multiforme is a highly aggressive brain tumor with a poor
prognosis, and advances in treatment have led to only marginal increases in overall …

Glioblastoma is the most prevalent and aggressive primary brain tumour for which total
tumour lysate-pulsed dendritic cell vaccination is currently under clinical evaluation …